RSLS vs. QNRX, NMRD, OSA, TNON, DYNT, BJDX, OSAP, INVO, SINT, and UTRS
Should you be buying ReShape Lifesciences stock or one of its competitors? The main competitors of ReShape Lifesciences include Quoin Pharmaceuticals (QNRX), Nemaura Medical (NMRD), ProSomnus (OSA), Tenon Medical (TNON), Dynatronics (DYNT), Bluejay Diagnostics (BJDX), ProSomnus (OSAP), INVO Bioscience (INVO), Sintx Technologies (SINT), and Minerva Surgical (UTRS). These companies are all part of the "surgical & medical instruments" industry.
Quoin Pharmaceuticals (NASDAQ:QNRX) and ReShape Lifesciences (NASDAQ:RSLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership.
Quoin Pharmaceuticals has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.
Quoin Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 534.92%. ReShape Lifesciences has a consensus price target of $0.00, indicating a potential downside of 100.00%. Given ReShape Lifesciences' higher possible upside, research analysts clearly believe Quoin Pharmaceuticals is more favorable than ReShape Lifesciences.
Quoin Pharmaceuticals has a net margin of 0.00% compared to Quoin Pharmaceuticals' net margin of -131.22%. ReShape Lifesciences' return on equity of -105.09% beat Quoin Pharmaceuticals' return on equity.
In the previous week, Quoin Pharmaceuticals and Quoin Pharmaceuticals both had 1 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 1.00 beat ReShape Lifesciences' score of 0.67 indicating that ReShape Lifesciences is being referred to more favorably in the news media.
8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.1% of ReShape Lifesciences shares are owned by institutional investors. 3.3% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of ReShape Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
ReShape Lifesciences received 393 more outperform votes than Quoin Pharmaceuticals when rated by MarketBeat users. Likewise, 66.22% of users gave ReShape Lifesciences an outperform vote while only 55.56% of users gave Quoin Pharmaceuticals an outperform vote.
Quoin Pharmaceuticals has higher earnings, but lower revenue than ReShape Lifesciences.
Summary
Quoin Pharmaceuticals beats ReShape Lifesciences on 8 of the 13 factors compared between the two stocks.
Get ReShape Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RSLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ReShape Lifesciences Competitors List
Related Companies and Tools
